HC Wainwright Has Negative Outlook for MSLE Q3 Earnings

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate for Satellos Bioscience to a loss of $0.43 per share from $0.36, while maintaining a Buy rating and $18 price target.
• Satellos recently reported a quarterly loss of $0.56 per share, missing consensus expectations of a $0.38 loss. Analysts project the company will remain loss-making in the near term, with an estimated full-year 2026 loss of $1.92 per share.
• Despite the weaker earnings outlook, analyst sentiment remains moderately positive: five analysts rate the stock Buy, one Hold and one Sell, producing a consensus target price of $19.75 versus the recent $9.81 share price.

Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Research analysts at HC Wainwright dropped their Q3 2026 earnings estimates for shares of Satellos Bioscience in a research report issued on Monday, August 17th. HC Wainwright analyst A. He now anticipates that the company will post earnings of ($0.43) per share for the quarter, down from their prior estimate of ($0.36). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Satellos Bioscience's current full-year earnings is ($1.85) per share. HC Wainwright also issued estimates for Satellos Bioscience's Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.92) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.51) EPS, FY2027 earnings at ($1.89) EPS, FY2028 earnings at ($1.88) EPS, FY2029 earnings at ($0.88) EPS and FY2030 earnings at $0.86 EPS.

Satellos Bioscience (NASDAQ:MSLE - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.18).

MSLE has been the subject of a number of other reports. Wall Street Zen upgraded Satellos Bioscience from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. Canaccord Genuity Group upgraded Satellos Bioscience to a "moderate buy" rating in a research report on Thursday, May 21st. Wells Fargo & Company set a $18.00 target price on Satellos Bioscience in a research note on Thursday, July 9th. Guggenheim started coverage on Satellos Bioscience in a research note on Tuesday, April 28th. They issued a "buy" rating and a $23.00 price target on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Satellos Bioscience in a research report on Friday, August 7th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Satellos Bioscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.75.

Satellos Bioscience Trading Down 1.3%

MSLE stock opened at $9.81 on Wednesday. The firm has a market capitalization of $204.44 million, a price-to-earnings ratio of -5.11 and a beta of 1.51. Satellos Bioscience has a 12-month low of $4.91 and a 12-month high of $13.39. The firm has a fifty day moving average price of $8.35.

Hedge Funds Weigh In On Satellos Bioscience

An institutional investor recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC raised its stake in Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) by 391.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 491,624 shares of the company's stock after purchasing an additional 391,624 shares during the quarter. Satellos Bioscience accounts for about 2.0% of Stonepine Capital Management LLC's portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned approximately 2.36% of Satellos Bioscience worth $3,723,291,000 as of its most recent filing with the Securities & Exchange Commission.

Key Satellos Bioscience News

Here are the key news stories impacting Satellos Bioscience this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $18.00 price target for Satellos Bioscience. The target implies substantial upside from the recent $9.81 reference price, indicating that the analyst still sees significant long-term value in the company’s pipeline and growth prospects. Satellos Bioscience Earns Buy Rating from HC Wainwright
• Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods, including Q3 2026 to $(0.43) from $(0.36), FY2026 to $(1.92) from $(1.60), and FY2027 to $(1.89) from $(1.76). Forecasts were also reduced for 2027–2030, with projected FY2030 profit lowered to $0.86 per share from $0.93. The revisions suggest higher expected losses and a slower path to profitability, which can weigh on a development-stage biotechnology stock.
• Negative Sentiment: The company remains loss-making, with analysts expecting a current-year loss of approximately $(1.85) per share. Satellos also previously reported quarterly EPS of $(0.56), missing the $(0.38) consensus estimate, reinforcing concerns about ongoing cash needs and execution risk.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source